World & BusinessDenmark's central bank reportedly doubles growth forecast on U.S. demand for Novo Nordisk drugs
Fortune says the growth is mainly due to Novo Nordisk's U.S. sales and production in early 2026. The Danish drugmaker is behind Ozempic and Wegovy.
TLDR
Fortune reports that U.S. demand for Novo Nordisk's weight-loss drugs prompted Denmark's central bank to double its national growth forecast. The report attributes the growth mainly to Novo's sales and production in the U.S. market in early 2026, illustrating the drugmaker's influence on Denmark's economic outlook.
Denmark's central bank reportedly doubles growth forecast on U.S. demand for Novo Nordisk drugs
Fortune says the growth is mainly due to Novo Nordisk's U.S. sales and production in early 2026. The Danish drugmaker is behind Ozempic and Wegovy.
TLDR
Fortune reports that U.S. demand for Novo Nordisk's weight-loss drugs prompted Denmark's central bank to double its national growth forecast. The report attributes the growth mainly to Novo's sales and production in the U.S. market in early 2026, illustrating the drugmaker's influence on Denmark's economic outlook.